Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis
- PMID: 40004847
- PMCID: PMC11856631
- DOI: 10.3390/jcm14041317
Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a relatively common progressive fibrotic interstitial lung disease associated with significant morbidity and mortality. The available medications for IPF only slow down the disease process, with lung transplantation the only option for a cure. Non-pharmacological therapies are significant adjuncts that can improve symptom burden and quality of life with minimal or no side effects. Supplemental oxygen can improve exercise capacity and the sensation of dyspnea in a significant portion of patients with resting or exertional hypoxemia and has been supported by several professional societies. Pulmonary rehabilitation is a comprehensive program that includes education and therapeutic exercises to improve patient stamina and strength. It is one of the few interventions that have been shown to produce a meaningful increase in a patient's exercise capacity, but its wide adoption is limited by availability, especially in rural areas. Sleep optimization with supplemental oxygen and positive airway pressure therapy should actively be investigated for all patients diagnosed with IPF. Although gastroesophageal reflux control with non-pharmacological means is still controversial as an intervention to reduce the rate of lung function decline, it can help control reflux symptoms and improve cough intensity. IPF patients should be educated on the importance of balanced nutrition and the potential benefits of screening for lung transplantation. Palliative medicine can help with symptom control and should be considered for all patients regardless severity, but especially in those in the later stages of disease.
Keywords: GERD; diet; idiopathic pulmonary fibrosis (IPF); interstitial lung disease (ILD); lung cancer; lung transplant; palliative care; pulmonary rehabilitation; sleep; supplemental oxygen.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis.Med Sci (Basel). 2018 Jul 24;6(3):59. doi: 10.3390/medsci6030059. Med Sci (Basel). 2018. PMID: 30042369 Free PMC article. Review.
-
Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease: A Multicenter Study.Chest. 2023 Feb;163(2):345-357. doi: 10.1016/j.chest.2022.08.2233. Epub 2022 Sep 8. Chest. 2023. PMID: 36089070
-
Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease.Am J Respir Crit Care Med. 2024 Oct 15;210(8):1035-1044. doi: 10.1164/rccm.202311-2101OC. Am J Respir Crit Care Med. 2024. PMID: 38536110
-
Interstitial Lung Disease: A Review.JAMA. 2024 May 21;331(19):1655-1665. doi: 10.1001/jama.2024.3669. JAMA. 2024. PMID: 38648021 Review.
-
Impact of gastroesophageal reflux disease on idiopathic pulmonary fibrosis and lung transplant recipients.Curr Opin Gastroenterol. 2022 Jul 1;38(4):411-416. doi: 10.1097/MOG.0000000000000841. Curr Opin Gastroenterol. 2022. PMID: 35762701 Review.
References
-
- King T.E., Jr., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glassberg M.K., Gorina E., Hopkins P.M., Kardatzke D., Lancaster L., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014;370:2083–2092. doi: 10.1056/NEJMoa1402582. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources